A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies
- Authors:
- more »
- Publication Date:
- Sponsoring Org.:
- USDOE
- OSTI Identifier:
- 1198084
- Resource Type:
- Published Article
- Journal Name:
- Cancer Cell
- Additional Journal Information:
- Journal Name: Cancer Cell Journal Volume: 20 Journal Issue: 4; Journal ID: ISSN 1535-6108
- Publisher:
- Elsevier
- Country of Publication:
- United States
- Language:
- English
Citation Formats
Schaefer, Gabriele, Haber, Lauric, Crocker, Lisa M., Shia, Steven, Shao, Lily, Dowbenko, Donald, Totpal, Klara, Wong, Anne, Lee, Chingwei V., Stawicki, Scott, Clark, Robyn, Fields, Carter, Lewis Phillips, Gail D., Prell, Rodney A., Danilenko, Dimitry M., Franke, Yvonne, Stephan, Jean-Philippe, Hwang, Jiyoung, Wu, Yan, Bostrom, Jenny, Sliwkowski, Mark X., Fuh, Germaine, and Eigenbrot, Charles. A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies. United States: N. p., 2011.
Web. doi:10.1016/j.ccr.2011.09.003.
Schaefer, Gabriele, Haber, Lauric, Crocker, Lisa M., Shia, Steven, Shao, Lily, Dowbenko, Donald, Totpal, Klara, Wong, Anne, Lee, Chingwei V., Stawicki, Scott, Clark, Robyn, Fields, Carter, Lewis Phillips, Gail D., Prell, Rodney A., Danilenko, Dimitry M., Franke, Yvonne, Stephan, Jean-Philippe, Hwang, Jiyoung, Wu, Yan, Bostrom, Jenny, Sliwkowski, Mark X., Fuh, Germaine, & Eigenbrot, Charles. A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies. United States. https://doi.org/10.1016/j.ccr.2011.09.003
Schaefer, Gabriele, Haber, Lauric, Crocker, Lisa M., Shia, Steven, Shao, Lily, Dowbenko, Donald, Totpal, Klara, Wong, Anne, Lee, Chingwei V., Stawicki, Scott, Clark, Robyn, Fields, Carter, Lewis Phillips, Gail D., Prell, Rodney A., Danilenko, Dimitry M., Franke, Yvonne, Stephan, Jean-Philippe, Hwang, Jiyoung, Wu, Yan, Bostrom, Jenny, Sliwkowski, Mark X., Fuh, Germaine, and Eigenbrot, Charles. Sat .
"A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies". United States. https://doi.org/10.1016/j.ccr.2011.09.003.
@article{osti_1198084,
title = {A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies},
author = {Schaefer, Gabriele and Haber, Lauric and Crocker, Lisa M. and Shia, Steven and Shao, Lily and Dowbenko, Donald and Totpal, Klara and Wong, Anne and Lee, Chingwei V. and Stawicki, Scott and Clark, Robyn and Fields, Carter and Lewis Phillips, Gail D. and Prell, Rodney A. and Danilenko, Dimitry M. and Franke, Yvonne and Stephan, Jean-Philippe and Hwang, Jiyoung and Wu, Yan and Bostrom, Jenny and Sliwkowski, Mark X. and Fuh, Germaine and Eigenbrot, Charles},
abstractNote = {},
doi = {10.1016/j.ccr.2011.09.003},
journal = {Cancer Cell},
number = 4,
volume = 20,
place = {United States},
year = {Sat Oct 01 00:00:00 EDT 2011},
month = {Sat Oct 01 00:00:00 EDT 2011}
}
Free Publicly Available Full Text
Publisher's Version of Record
https://doi.org/10.1016/j.ccr.2011.09.003
https://doi.org/10.1016/j.ccr.2011.09.003
Other availability
Search WorldCat to find libraries that may hold this journal
Cited by: 240 works
Citation information provided by
Web of Science
Web of Science
Save to My Library
You must Sign In or Create an Account in order to save documents to your library.
Works referenced in this record:
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
journal, May 2004
- Lynch, Thomas J.; Bell, Daphne W.; Sordella, Raffaella
- New England Journal of Medicine, Vol. 350, Issue 21
Pharmacogenomic and Pharmacoproteomic Studies of Cetuximab in Metastatic Colorectal Cancer: Biomarker Analysis of a Phase I Dose-Escalation Study
journal, March 2010
- Tabernero, Josep; Cervantes, Andres; Rivera, Fernando
- Journal of Clinical Oncology, Vol. 28, Issue 7
Phase I Pharmacokinetic/Pharmacodynamic Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Combination with Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in First-Line Treatment of Patients with Metastatic Colorectal Cancer
journal, January 2008
- Folprecht, G.; Tabernero, J.; Kohne, C. -H.
- Clinical Cancer Research, Vol. 14, Issue 1
Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network
journal, August 2007
- Ritter, Christoph A.; Perez-Torres, Marianela; Rinehart, Cammie
- Clinical Cancer Research, Vol. 13, Issue 16
FcγRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck
journal, November 2008
- Taylor, Rodney J.; Chan, Siaw-Lin; Wood, Aaron
- Cancer Immunology, Immunotherapy, Vol. 58, Issue 7
Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3
journal, December 2009
- Jura, N.; Shan, Y.; Cao, X.
- Proceedings of the National Academy of Sciences, Vol. 106, Issue 51
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer
journal, July 2006
- Zhou, Bin-Bing S.; Peyton, Michael; He, Biao
- Cancer Cell, Vol. 10, Issue 1
Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.
journal, May 1994
- Sliwkowski, M. X.; Schaefer, G.; Akita, R. W.
- Journal of Biological Chemistry, Vol. 269, Issue 20
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors
journal, January 1984
- Chou, Ting-Chao; Talalay, Paul
- Advances in Enzyme Regulation, Vol. 22
γ-Heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175
journal, September 1997
- Schaefer, Gabriele; Fitzpatrick, V. Danial; Sliwkowski, Mark X.
- Oncogene, Vol. 15, Issue 12
Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site
journal, March 2009
- Bostrom, J.; Yu, S. -F.; Kan, D.
- Science, Vol. 323, Issue 5921
Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage
journal, November 2009
- Schneider-Merck, Tanja; Lammerts van Bueren, Jeroen J.; Berger, Sven
- The Journal of Immunology, Vol. 184, Issue 1
TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer
journal, September 2005
- Herbst, Roy S.; Prager, Diane; Hermann, Robert
- Journal of Clinical Oncology, Vol. 23, Issue 25
Engineering of therapeutic antibodies to minimize immunogenicity and optimize function
journal, August 2006
- Presta, Leonard G.
- Advanced Drug Delivery Reviews, Vol. 58, Issue 5-6
Erlotinib Directly Inhibits HER2 Kinase Activation and Downstream Signaling Events in Intact Cells Lacking Epidermal Growth Factor Receptor Expression
journal, February 2007
- Schaefer, Gabriele; Shao, Lihua; Totpal, Klara
- Cancer Research, Vol. 67, Issue 3
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
journal, June 2004
- Paez, J. G.
- Science, Vol. 304, Issue 5676
HER2 Oncogenic Function Escapes EGFR Tyrosine Kinase Inhibitors via Activation of Alternative HER Receptors in Breast Cancer Cells
journal, August 2008
- Kong, Anthony; Calleja, Véronique; Leboucher, Pierre
- PLoS ONE, Vol. 3, Issue 8
NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancer
journal, July 2000
- Olayioye, M. A.
- The EMBO Journal, Vol. 19, Issue 13
Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
journal, February 2008
- Wheeler, D. L.; Huang, S.; Kruser, T. J.
- Oncogene, Vol. 27, Issue 28
Identification of Biomarkers in Human Head and Neck Tumor Cell Lines That Predict For In Vitro Sensitivity to Gefitinib
journal, June 2009
- Hickinson, D. Mark; Marshall, Gayle B.; Beran, Garry J.
- Clinical and Translational Science, Vol. 2, Issue 3
Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor-PI3K Axis
journal, June 2009
- Schoeberl, B.; Pace, E. A.; Fitzgerald, J. B.
- Science Signaling, Vol. 2, Issue 77
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
journal, April 2005
- Li, Shiqing; Schmitz, Karl R.; Jeffrey, Philip D.
- Cancer Cell, Vol. 7, Issue 4
HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer Therapy
journal, February 2010
- Campbell, Marcia R.; Amin, Dhara; Moasser, Mark M.
- Clinical Cancer Research, Vol. 16, Issue 5
T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells
journal, June 2010
- Lutterbuese, Ralf; Raum, Tobias; Kischel, Roman
- Proceedings of the National Academy of Sciences, Vol. 107, Issue 28
The erbB3 gene product is a receptor for heregulin.
journal, May 1994
- Carraway, K. L.; Sliwkowski, M. X.; Akita, R.
- Journal of Biological Chemistry, Vol. 269, Issue 19
Structure of the Extracellular Region of HER3 Reveals an Interdomain Tether
journal, August 2002
- Cho, H. -S.
- Science, Vol. 297, Issue 5585
Acquired resistance to tyrosine kinase inhibitors during cancer therapy
journal, February 2008
- Engelman, Jeffrey A.; Settleman, Jeffrey
- Current Opinion in Genetics & Development, Vol. 18, Issue 1
Therapeutic potential of ABX-EGF: A fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment
journal, February 2002
- Lynch, David H.; Yang, Xiao-Dong
- Seminars in Oncology, Vol. 29, Issue 1
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
journal, September 2011
- Yonesaka, Kimio; Zejnullahu, Kreshnik; Okamoto, Isamu
- Science Translational Medicine, Vol. 3, Issue 99
HER Kinase Axis Receptor Dimer Partner Switching Occurs in Response to EGFR Tyrosine Kinase Inhibition despite Failure to Block Cellular Proliferation
journal, February 2010
- Jain, Anjali; Penuel, Elicia; Mink, Sheldon
- Cancer Research, Vol. 70, Issue 5
The IgG Fc receptor family
journal, June 1998
- Gessner, J. E.; Heiken, H.; Tamm, A.
- Annals of Hematology, Vol. 76, Issue 6
Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment
journal, June 2009
- Jura, Natalia; Endres, Nicholas F.; Engel, Kate
- Cell, Vol. 137, Issue 7
Superior In vivo Efficacy of Afucosylated Trastuzumab in the Treatment of HER2-Amplified Breast Cancer
journal, May 2010
- Junttila, Teemu T.; Parsons, Kathryn; Olsson, Christine
- Cancer Research, Vol. 70, Issue 11
High-affinity Human Antibodies from Phage-displayed Synthetic Fab Libraries with a Single Framework Scaffold
journal, July 2004
- Lee, Chingwei V.; Liang, Wei-Ching; Dennis, Mark S.
- Journal of Molecular Biology, Vol. 340, Issue 5
The Role of Gefitinib in Lung Cancer Treatment
journal, June 2004
- Giaccone, Giuseppe
- Clinical Cancer Research, Vol. 10, Issue 12
ErbB receptors and signaling pathways in cancer
journal, April 2009
- Hynes, Nancy E.; MacDonald, Gwen
- Current Opinion in Cell Biology, Vol. 21, Issue 2
Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity
journal, August 2006
- Buck, Elizabeth; Eyzaguirre, Alexandra; Haley, John D.
- Molecular Cancer Therapeutics, Vol. 5, Issue 8
EGFR Antibodies in Colorectal Cancer: Where Do They Belong?
journal, November 2010
- Grothey, Axel
- Journal of Clinical Oncology, Vol. 28, Issue 31
Skin toxicities associated with epidermal growth factor receptor inhibitors
journal, May 2009
- Li, Tianhong; Perez-Soler, Roman
- Targeted Oncology, Vol. 4, Issue 2
Dual Mode of Action of a Human Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Cancer Therapy
journal, September 2004
- Bleeker, Wim K.; Lammerts van Bueren, Jeroen J.; van Ojik, Heidi H.
- The Journal of Immunology, Vol. 173, Issue 7
EGFR Antagonists in Cancer Treatment
journal, March 2008
- Ciardiello, Fortunato; Tortora, Giampaolo
- New England Journal of Medicine, Vol. 358, Issue 11
An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation
journal, March 2010
- Schoeberl, B.; Faber, A. C.; Li, D.
- Cancer Research, Vol. 70, Issue 6
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
journal, August 2002
- Agus, David B.; Akita, Robert W.; Fox, William D.
- Cancer Cell, Vol. 2, Issue 2
Identification of c-erbB-3 binding sites for phosphatidylinositol 3′-kinase and SHC using an EGF receptor/c-erbB-3 chimera.
journal, June 1994
- Prigent, S. A.; Gullick, W. J.
- The EMBO Journal, Vol. 13, Issue 12
Targeting the function of the HER2 oncogene in human cancer therapeutics
journal, May 2007
- Moasser, M. M.
- Oncogene, Vol. 26, Issue 46
A quantitative protein interaction network for the ErbB receptors using protein microarrays
journal, November 2005
- Jones, Richard B.; Gordus, Andrew; Krall, Jordan A.
- Nature, Vol. 439, Issue 7073
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines
journal, February 2005
- Engelman, J. A.; Janne, P. A.; Mermel, C.
- Proceedings of the National Academy of Sciences, Vol. 102, Issue 10
Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells
journal, November 2006
- Lee, Chingwei V.; Hymowitz, Sarah G.; Wallweber, Heidi J.
- Blood, Vol. 108, Issue 9